A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

@inproceedings{Pratz2010APS,
  title={A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias},
  author={Keith W Pratz and Eunpi Cho and Mark J Levis and Judith E. Karp and Steven D Gore and Michael A. McDevitt and Adam Stine and Mingming Zhao and Sharyn D. Baker and Michael Anthony Carducci and John Joseph Wright and Michelle A. Rudek and Bruce D. Smith},
  booktitle={Leukemia},
  year={2010}
}
We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen. Fifteen patients with advanced leukemia (12 with acute myeloid leukemia, 2 with acute lymphoblastic leukemia, 1 with biphenotypic) and a median age of 63 (range 37–85) years were enrolled and treated on a dose escalation trial. Toxicities ⩾grade 3 were present in 55% of cycles and the maximum tolerated dose (MTD… CONTINUE READING
Highly Cited
This paper has 46 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 27 citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Update of a Phase I Study of Sorafenib in Patients with Refractory/Relapsed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • J JrDelmonte, HM Kantarjian, M Andreeff, S Faderl, JJ Wright, W Zhang
  • ASH Annual Meeting Abstracts
  • 2007
1 Excerpt